0 trading plans running, 15 Form 144 notices for $41.4M
10-Q, 10-K and Form 144What WK's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Sep 11, 2023 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Robert H. Herz member of our board of directors |
Adopted 10b5-1 plan | May 8, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteOn May 8, 2025, The Robert H. Herz Irrevocable Trust, a trust of which the trustee is the spouse of Robert H. Herz, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c). The Rule 10b5-1 trading arrangement provides for the sale of up to 5,000 shares of the Company's Class A common stock, until February 16, 2026 or earlier if all transactions under the trading arrangement are completed. The first transaction under the Rule 10b5-1 Plan may not occur until August 7, 2025. | |||||
| Michael Hawkins Executive Vice President of Sales |
Ended 10b5-1 plan | Feb 1, 2024 | 10-Q May 2, 2024 | ||
What the company wroteOn February 1, 2024, the pre-arranged stock trading plan pursuant to rule 10b5-1, adopted by Michael Hawkins, Executive Vice President of Sales, on September 11, 2023, automatically terminated pursuant to its terms. The expired plan provided for the potential sale of up to 20,152 shares of the Company's Class A common stock through February 9, 2024. | |||||
| Michael Hawkins Executive Vice President of Sales |
Adopted 10b5-1 plan | Sep 11, 2023 | 10-Q Oct 30, 2023 | ||
What the company wroteOn September 11, 2023, Michael Hawkins, Executive Vice President of Sales, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,152 shares of the Company's Class A common stock until February 9, 2024. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 2, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 20, 2026 | BRANDON ZIEGLER Officer |
6,571 | $499K |
| Aug 5, 2026 | Matthew Rizai 10% Stockholder |
20,000 | $1.2M |
| Jul 16, 2026 | Matthew Rizai 10% Stockholder |
30,000 | $1.7M |
| Jul 1, 2026 | MATTHEW RIZAI 10% Stockholder |
120,000 | $6.0M |
| Jun 17, 2026 | MATTHEW RIZAI 10% Stockholder |
20,204 | $987K |
| May 29, 2026 | ROBERT HERZ Director |
1,000 | $50K |
| Mar 5, 2026 | Matthew Rizai 10% stockholder |
71,429 | $4.6M |
| Feb 24, 2026 | JILL KLINDT Officer |
16,040 | $942K |
| Feb 20, 2026 | Matthew Rizai 10% Shareholder |
50,000 | $3.0M |
| Jan 21, 2026 | Matthew Rizai 10% stockholder |
30,364 | $2.4M |
| Jan 2, 2026 | Matthew Rizai 10% Stockholder |
25,980 | $2.2M |
| Dec 17, 2025 | MATTHEW RIZAI 10% Stockholder |
60,000 | $5.3M |
| Dec 10, 2025 | ROBERT HERZ Director |
1,500 | $137K |
| Dec 4, 2025 | MICHAEL HAWKINS Officer |
12,000 | $1.1M |
| Nov 25, 2025 | MULCAHY DAVID S. Director |
120,000 | $11.1M |
Show the other 7 notices
From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WK/export.csv") into a cell.